• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.

作者信息

Guolo Fabio, Minetto Paola, Clavio Marino, Miglino Maurizio, Colombo Nicoletta, Cagnetta Antonia, Cea Michele, Marcolin Riccardo, Todiere Andrea, Ballerini Filippo, Gobbi Marco, Lemoli Roberto Massimo

机构信息

Clinic of Haematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy.

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

出版信息

Br J Haematol. 2019 Sep;186(6):e223-e225. doi: 10.1111/bjh.16116. Epub 2019 Jul 26.

DOI:10.1111/bjh.16116
PMID:31348524
Abstract
摘要

相似文献

1
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.伴有NPM1突变的急性髓系白血病的纵向微小残留病（MRD）评估：从分子复发的定义到MRD驱动的挽救治疗方法
Br J Haematol. 2019 Sep;186(6):e223-e225. doi: 10.1111/bjh.16116. Epub 2019 Jul 26.
2
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.基于数字液滴 PCR 的移植前 NPM1 突变负担绝对定量可预测急性髓系白血病患者的复发。
Ann Hematol. 2018 Oct;97(10):1757-1765. doi: 10.1007/s00277-018-3373-y. Epub 2018 May 22.
3
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.伴有 NPM1 突变和有利的欧洲白血病网分类的急性髓细胞白血病：基于微小残留病灶的抢先干预后的结果。
Br J Haematol. 2020 Oct;191(1):52-61. doi: 10.1111/bjh.16857. Epub 2020 Jun 8.
4
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.由于2019年冠状病毒病大流行，在采用降低强度的急性髓系白血病（AML）化疗方案治疗NPM1突变型急性髓系白血病（AML）后，对于如何使用既定的微小残留病监测存在担忧。
Br J Haematol. 2020 Aug;190(4):e208-e210. doi: 10.1111/bjh.16985. Epub 2020 Jul 26.
5
The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia.在实时定量聚合酶链反应和流式细胞术检测到 NPM1 突变的急性髓系白血病结果不一致的情况下，微小残留病的预测价值。
Ann Hematol. 2020 Jan;99(1):73-82. doi: 10.1007/s00277-019-03861-1. Epub 2019 Nov 25.
6
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.采用氟达拉滨、阿糖胞苷和伊达比星（FLAI）诱导治疗急性髓系白血病（AML）后进行早期微小残留病评估可提供最有用的预后信息。
Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23.
7
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.以外周血作为骨髓的替代来源监测成人急性髓系白血病微小残留病
Haematologica. 2007 May;92(5):605-11. doi: 10.3324/haematol.10432.
8
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.维奈托克联合低强度化疗诱导急性髓系白血病中 NPM1 突变型可测量残留病的快速消除。
Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26.
9
Do we still need morphologic evaluation in new era of advanced minimal residual disease analyses?在先进的微小残留病分析新时代，我们仍然需要形态学评估吗？
Int J Lab Hematol. 2019 Dec;41(6):e145-e147. doi: 10.1111/ijlh.13045. Epub 2019 May 3.
10
Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.基于 FLT3 内部串联重复的成人急性髓细胞白血病微小残留病监测。
Leuk Res. 2012 Mar;36(3):316-23. doi: 10.1016/j.leukres.2011.11.002. Epub 2011 Nov 29.

引用本文的文献

1
Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival.仅 FLT3-ITD 共突变对伴有 NPM1 突变的急性髓系白血病患者没有不良影响，但伴有 DNMT3A 共突变或 MRD2 减少 < 3log 预示着不良生存。
Ann Hematol. 2024 Nov;103(11):4525-4535. doi: 10.1007/s00277-024-06001-6. Epub 2024 Sep 17.
2
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.初治强化疗后伴 CBF 或 NPM1 突变的急性髓系白血病患者的分子复发 - FILO 研究。
Leukemia. 2024 Sep;38(9):1949-1957. doi: 10.1038/s41375-024-02335-2. Epub 2024 Jul 17.
3
Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?社论：急性髓系白血病（AML）：是时候采用基于微小残留病（MRD）的治疗方法了吗？
Front Oncol. 2022 Sep 9;12:1020185. doi: 10.3389/fonc.2022.1020185. eCollection 2022.
4
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of -ITD in Mutated AML, Irrespectively of -ITD Allelic Burden.基于氟达拉滨、大剂量阿糖胞苷和伊达比星的诱导治疗可能克服-ITD在突变型急性髓系白血病中的不良预后影响，而与-ITD等位基因负担无关。
Cancers (Basel). 2020 Dec 24;13(1):34. doi: 10.3390/cancers13010034.
5
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.维奈托克联合低强度化疗诱导急性髓系白血病中 NPM1 突变型可测量残留病的快速消除。
Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26.